Recent News

• 09.24.2025 - Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
• 09.24.2025 - Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
• 09.15.2025 - Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025
• 09.15.2025 - Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025
• 09.09.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.09.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.08.2025 - Morgan Stanley 23rd Annual Global Healthcare Conference
• 09.08.2025 - Morgan Stanley 23rd Annual Global Healthcare Conference
• 09.08.2025 - Morgan Stanley 23rd Annual Global Healthcare Conference
• 09.08.2025 - Morgan Stanley 23rd Annual Global Healthcare Conference

Recent Filings